Lung cancer and hormone replacement therapy: Association in the vitamins and lifestyle study

Christopher G. Slatore, Jason W. Chien, David H. Au, Jessie A. Satia, Emily White

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Purpose: Lung cancer is the leading cause of cancer-related mortality among women. The role of hormone replacement therapy (HRT) in lung cancer development is unclear. Patients and Methods: We evaluated a prospective cohort of 36,588 peri- and postmenopausal women aged 50 to 76 years from Washington State recruited in 2000 to 2002 (Vitamins and Lifestyle [VITAL] Study). Lung cancer cases (n = 344) were identified through the Seattle-Puget Sound Surveillance, Epidemiology, and End Results cancer registry during 6 years of follow-up. Hazard ratios (HRs) associated with use and duration of specific HRT formulations were calculated for total incident lung cancer, specific morphologies, and cancer by stage at diagnosis. Results: After adjusting for smoking, age, and other potential confounders, there was an increased risk of incident lung cancer associated with increasing duration of estrogen plus progestin (E+P) use (HR = 1.27 for E+P use 1 to 9 years, 95% CI, 0.91 to 1.78; and HR = 1.48 for E+P use ≥ 10 years, 95% CI, 1.03 to 2.12; P for trend = .03). There was no association with duration of unopposed estrogen use. Duration of E+P use was associated with an advanced stage at diagnosis (P for trend = .03). Conclusion: Use of E+P increased the risk of incident lung cancer in a duration-dependent manner, with an approximate 50% increased risk for use of 10 years or longer. These findings may be helpful for informing women of their risk of developing lung cancer and delineating important pathways involved in hormone metabolism and lung cancer.

Original languageEnglish (US)
Pages (from-to)1540-1546
Number of pages7
JournalJournal of Clinical Oncology
Volume28
Issue number9
DOIs
StatePublished - Mar 20 2010

Fingerprint

Hormone Replacement Therapy
Vitamins
Life Style
Lung Neoplasms
Estrogens
Neoplasms
Progestins
Registries
Epidemiology
Smoking
Hormones
Mortality

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Lung cancer and hormone replacement therapy : Association in the vitamins and lifestyle study. / Slatore, Christopher G.; Chien, Jason W.; Au, David H.; Satia, Jessie A.; White, Emily.

In: Journal of Clinical Oncology, Vol. 28, No. 9, 20.03.2010, p. 1540-1546.

Research output: Contribution to journalArticle

Slatore, Christopher G. ; Chien, Jason W. ; Au, David H. ; Satia, Jessie A. ; White, Emily. / Lung cancer and hormone replacement therapy : Association in the vitamins and lifestyle study. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 9. pp. 1540-1546.
@article{96c9eb9aa5a54b6aaf8d816a92c9afbb,
title = "Lung cancer and hormone replacement therapy: Association in the vitamins and lifestyle study",
abstract = "Purpose: Lung cancer is the leading cause of cancer-related mortality among women. The role of hormone replacement therapy (HRT) in lung cancer development is unclear. Patients and Methods: We evaluated a prospective cohort of 36,588 peri- and postmenopausal women aged 50 to 76 years from Washington State recruited in 2000 to 2002 (Vitamins and Lifestyle [VITAL] Study). Lung cancer cases (n = 344) were identified through the Seattle-Puget Sound Surveillance, Epidemiology, and End Results cancer registry during 6 years of follow-up. Hazard ratios (HRs) associated with use and duration of specific HRT formulations were calculated for total incident lung cancer, specific morphologies, and cancer by stage at diagnosis. Results: After adjusting for smoking, age, and other potential confounders, there was an increased risk of incident lung cancer associated with increasing duration of estrogen plus progestin (E+P) use (HR = 1.27 for E+P use 1 to 9 years, 95{\%} CI, 0.91 to 1.78; and HR = 1.48 for E+P use ≥ 10 years, 95{\%} CI, 1.03 to 2.12; P for trend = .03). There was no association with duration of unopposed estrogen use. Duration of E+P use was associated with an advanced stage at diagnosis (P for trend = .03). Conclusion: Use of E+P increased the risk of incident lung cancer in a duration-dependent manner, with an approximate 50{\%} increased risk for use of 10 years or longer. These findings may be helpful for informing women of their risk of developing lung cancer and delineating important pathways involved in hormone metabolism and lung cancer.",
author = "Slatore, {Christopher G.} and Chien, {Jason W.} and Au, {David H.} and Satia, {Jessie A.} and Emily White",
year = "2010",
month = "3",
day = "20",
doi = "10.1200/JCO.2009.25.9739",
language = "English (US)",
volume = "28",
pages = "1540--1546",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Lung cancer and hormone replacement therapy

T2 - Association in the vitamins and lifestyle study

AU - Slatore, Christopher G.

AU - Chien, Jason W.

AU - Au, David H.

AU - Satia, Jessie A.

AU - White, Emily

PY - 2010/3/20

Y1 - 2010/3/20

N2 - Purpose: Lung cancer is the leading cause of cancer-related mortality among women. The role of hormone replacement therapy (HRT) in lung cancer development is unclear. Patients and Methods: We evaluated a prospective cohort of 36,588 peri- and postmenopausal women aged 50 to 76 years from Washington State recruited in 2000 to 2002 (Vitamins and Lifestyle [VITAL] Study). Lung cancer cases (n = 344) were identified through the Seattle-Puget Sound Surveillance, Epidemiology, and End Results cancer registry during 6 years of follow-up. Hazard ratios (HRs) associated with use and duration of specific HRT formulations were calculated for total incident lung cancer, specific morphologies, and cancer by stage at diagnosis. Results: After adjusting for smoking, age, and other potential confounders, there was an increased risk of incident lung cancer associated with increasing duration of estrogen plus progestin (E+P) use (HR = 1.27 for E+P use 1 to 9 years, 95% CI, 0.91 to 1.78; and HR = 1.48 for E+P use ≥ 10 years, 95% CI, 1.03 to 2.12; P for trend = .03). There was no association with duration of unopposed estrogen use. Duration of E+P use was associated with an advanced stage at diagnosis (P for trend = .03). Conclusion: Use of E+P increased the risk of incident lung cancer in a duration-dependent manner, with an approximate 50% increased risk for use of 10 years or longer. These findings may be helpful for informing women of their risk of developing lung cancer and delineating important pathways involved in hormone metabolism and lung cancer.

AB - Purpose: Lung cancer is the leading cause of cancer-related mortality among women. The role of hormone replacement therapy (HRT) in lung cancer development is unclear. Patients and Methods: We evaluated a prospective cohort of 36,588 peri- and postmenopausal women aged 50 to 76 years from Washington State recruited in 2000 to 2002 (Vitamins and Lifestyle [VITAL] Study). Lung cancer cases (n = 344) were identified through the Seattle-Puget Sound Surveillance, Epidemiology, and End Results cancer registry during 6 years of follow-up. Hazard ratios (HRs) associated with use and duration of specific HRT formulations were calculated for total incident lung cancer, specific morphologies, and cancer by stage at diagnosis. Results: After adjusting for smoking, age, and other potential confounders, there was an increased risk of incident lung cancer associated with increasing duration of estrogen plus progestin (E+P) use (HR = 1.27 for E+P use 1 to 9 years, 95% CI, 0.91 to 1.78; and HR = 1.48 for E+P use ≥ 10 years, 95% CI, 1.03 to 2.12; P for trend = .03). There was no association with duration of unopposed estrogen use. Duration of E+P use was associated with an advanced stage at diagnosis (P for trend = .03). Conclusion: Use of E+P increased the risk of incident lung cancer in a duration-dependent manner, with an approximate 50% increased risk for use of 10 years or longer. These findings may be helpful for informing women of their risk of developing lung cancer and delineating important pathways involved in hormone metabolism and lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=77951884321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951884321&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.25.9739

DO - 10.1200/JCO.2009.25.9739

M3 - Article

C2 - 20159813

AN - SCOPUS:77951884321

VL - 28

SP - 1540

EP - 1546

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -